Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Biogen
Biogen
Biogen jettisons AMD drug, providing Catalyst for ex-partner's hunt for strategic alternatives
Fierce Biotech
Wed, 03/16/22 - 10:10 am
Biogen
dry age-related macular degeneration
Catalyst Biosciences
CB 2782-PEG
Eisai hands off responsibility for Aduhelm to Biogen
Pharmaforum
Tue, 03/15/22 - 11:43 am
Eisai
Biogen
Aduhelm
Alzheimer's disease
Biogen Announces New Spinraza Data Ahead of Presentation
BioSpace
Mon, 03/14/22 - 11:39 pm
Biogen
Spinraza
SMA
spinal muscular atrophy
Alzheimer's patient groups pressure U.S. to pay for Biogen drug
Reuters
Sun, 03/13/22 - 11:07 pm
Alzheimer's disease
Biogen
Aduhelm
patient groups
A trio of amyloid-targeted Alzheimer's drugs will soon see key results, but an analyst predicts only 50-50 odds for one
Endpoints
Wed, 03/9/22 - 11:09 pm
Alzheimer's disease
clinical trials
Roche
Eli Lilly
Biogen
donanemab
lecanemab
gantenerumab
Biogen's Aduhelm still has blockbuster potential if everything breaks right: analyst
Fierce Pharma
Fri, 03/4/22 - 09:47 am
Biogen
Aduhelm
Alzheimer's disease
physicians
analysts
Biogen, struggling to sell Alzheimer's drug, begins layoffs to save money
BioPharma Dive
Thu, 03/3/22 - 12:12 pm
Biogen
layoffs
Aduhelm
Alzheimer's disease
3 more deaths among patients on Biogen's Aduhelm fuel safety concerns, though no link established: analyst
Fierce Pharma
Wed, 02/16/22 - 11:19 pm
Biogen
Aduhelm
Alzheimer's disease
patient deaths
Sage claims new data show depression drug works, but doubts remain
Biopharma Dive
Wed, 02/16/22 - 11:05 pm
SAGE Therapeutics
Biogen
depression
clinical trials
zuranolone
Eli Lilly and Roche ask CMS not to be lumped in with Aduhelm’s restrictive judgment
Endpoints
Mon, 02/14/22 - 11:06 am
Eli Lilly
Roche
Biogen
Alzheimer's disease
Aduhelm
CMS
Biogen and Xbrane in deal on rheumatoid arthritis targeting biosimilar
Biopharma Reporter
Mon, 02/14/22 - 11:04 am
Biogen
Xbrane Biopharma
monoclonal antibodies
Xcimzane
Cimzia
rheumatoid arthritis
What to Expect From Biogen's $2.3 Billion Shopping Spree
Motley Fool
Sat, 02/12/22 - 11:47 pm
Biogen
M&A
Aurinia Pharmaceuticals
Biohaven
With sotrovimab in the balance, Biogen vet reunites with George Scangos at Vir; First woman to chair PhRMA has more in store at Takeda
Endpoints
Fri, 02/11/22 - 10:11 am
Biogen
Vir Biotechnology
GSK
Johanna Friedl-Naderer
Takeda
PhRMA
Eisai bites back against restricted coverage plan for Aduhelm
Pharmaforum
Thu, 02/10/22 - 10:16 am
Eisai
Biogen
Aduhelm
Alzheimer's disease
FDA
CMS
Backing Biogen, 75+ House Republicans call on CMS to abandon its decision to limit amyloid-targeted Alzheimer's drugs to trials
Endpoints
Wed, 02/9/22 - 10:53 pm
Biogen
Aduhelm
CMS
Alzheimer's disease
Biogen says U.S. FTC, SEC probing Alzheimer's disease drug
Reuters
Mon, 02/7/22 - 11:26 pm
Biogen
Aduhelm
FTC
SEC
Alzheimer's disease
After disastrous start to launch, Biogen still expects 'minimal' sales from Aduhelm this year
Fierce Pharma
Thu, 02/3/22 - 11:45 am
Biogen
earnings
Aduhelm
Alzheimer's disease
Biogen buys into fast-advancing Roche cancer drug
BioPharma Dive
Tue, 02/1/22 - 11:30 pm
Biogen
Roche
lymphoma
cancer
CMS' Biogen decision could spell problems for Lilly, Roche Alzheimer's drugs, half of surveyed neurologists say
Fierce Pharma
Tue, 02/1/22 - 10:50 am
CMS
Biogen
Aduhelm
Eli Lilly
Roche
Alzheimer's disease
Biogen promises increased diversity in Phase 4 Aduhelm trial
Biopharma Reporter
Tue, 02/1/22 - 10:41 am
Biogen
Aduhelm
clinical trials
clinical trial diversity
Pages
« first
‹ previous
…
8
9
10
11
12
13
14
15
16
…
next ›
last »